X0306 4 2022-08-22 1 0000920465 LA JOLLA PHARMACEUTICAL CO LJPC 0001759910 Hearne Michael S C/O LA JOLLA PHARMACEUTICAL COMPANY 201 JONES ROAD, SUITE 400 WALTHAM MA 02451 0 1 0 0 Chief Financial Officer Common Stock 2022-08-22 4 D 0 10186 6.23 D 0 D Common Stock 2022-08-22 4 U 0 9607934 6.23 D 0 I BY LP Employee Stock Option (Right to Buy) 4.55 2022-08-22 4 D 0 100000 D Common Stock 100000 0 D Employee Stock Option (Right to Buy) 3.91 2022-08-22 4 D 0 169 D Common Stock 169 0 D Employee Stock Option (Right to Buy) 3.40 2022-08-22 4 D 0 196 D Common Stock 196 0 D Employee Stock Option (Right to Buy) 4.68 2022-08-22 4 D 0 141 D Common Stock 141 0 D Employee Stock Option (Right to Buy) 4.97 2022-08-22 4 D 0 134 D Common Stock 134 0 D Employee Stock Option (Right to Buy) 4.53 2022-08-22 4 D 0 52191 D Common Stock 52191 0 D Employee Stock Option (Right to Buy) 4.50 2022-08-22 4 D 0 147 D Common Stock 147 0 D Employee Stock Option (Right to Buy) 3.88 2022-08-22 4 D 0 1648 D Common Stock 1648 0 D Employee Stock Option (Right to Buy) 5.35 2022-08-22 4 D 0 136 D Common Stock 136 0 D Employee Stock Option (Right to Buy) 6.12 2022-08-22 4 D 0 118 D Common Stock 118 0 D Employee Stock Option (Right to Buy) 6.71 2022-08-22 4 D 0 108 D Common Stock 108 0 D Employee Stock Option (Right to Buy) 5.24 2022-08-22 4 D 0 139 D Common Stock 139 0 D Employee Stock Option (Right to Buy) 5.71 2022-08-22 4 D 0 127 D Common Stock 127 0 D Employee Stock Option (Right to Buy) 4.24 2022-08-22 4 D 0 172 D Common Stock 172 0 D Employee Stock Option (Right to Buy) 4.18 2022-08-22 4 D 0 173 D Common Stock 173 0 D Employee Stock Option (Right to Buy) 4.44 2022-08-22 4 D 0 164 D Common Stock 164 0 D Employee Stock Option (Right to Buy) 3.76 2022-08-22 4 D 0 386 D Common Stock 386 0 D Employee Stock Option (Right to Buy) 4.30 2022-08-22 4 D 0 169 D Common Stock 169 0 D Employee Stock Option (Right to Buy) 4.90 2022-08-22 4 D 0 148 D Common Stock 148 0 D Employee Stock Option (Right to Buy) 4.28 2022-08-22 4 D 0 170 D Common Stock 170 0 D Employee Stock Option (Right to Buy) 3.61 2022-08-22 4 D 0 201 D Common Stock 201 0 D Employee Stock Option (Right to Buy) 3.99 2022-08-22 4 D 0 728 D Common Stock 728 0 D Employee Stock Option (Right to Buy) 3.96 2022-08-22 4 D 0 373 D Common Stock 373 0 D Employee Stock Option (Right to Buy) 4.02 2022-08-22 4 D 0 181 D Common Stock 181 0 D Employee Stock Option (Right to Buy) 4.01 2022-08-22 4 D 0 558 D Common Stock 558 0 D Employee Stock Option (Right to Buy) 3.90 2022-08-22 4 D 0 186 D Common Stock 186 0 D Employee Stock Option (Right to Buy) 4.21 2022-08-22 4 D 0 173 D Common Stock 173 0 D Employee Stock Option (Right to Buy) 4.61 2022-08-22 4 D 0 157 D Common Stock 157 0 D Employee Stock Option (Right to Buy) 4.81 2022-08-22 4 D 0 78552 D Common Stock 78552 0 D Employee Stock Option (Right to Buy) 4.92 2022-08-22 4 D 0 148 D Common Stock 148 0 D This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $6.23 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. The Shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Tang Capital Management, LLC ("TCM") is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as the Chief Financial Officer of TCM. Mr. Hearne has a pecuniary interest in the shares beneficially held by TCP. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. Form 1 of 2 /s/ Michael Hearne 2022-08-24